Potency of Moderna, Pfizer vaccines weaker against epsilon COVID-19 variant
06 Jul 2021
byTristan Manalac
The novel epsilon variant of SARS-CoV-2, first detected in California, US, carries mutations in the spike (S) protein and N-terminal (NTD) and receptor-binding (RBD) domains that could render neutralizing antibodies (nAbs) induced by mRNA-based vaccines weaker, according to a recent study.
